Payment overview · 2025
General Payments
$2,233.58
88 reported records · 15 companies
Healthcare provider profile · identity verified
Henry C Echiverri, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WARRENVILLE, IL · NPI 1356347264
Verified facts
What the public records show
CMS Open Payments records show Henry C Echiverri, MD received $2,233.58 in general payments during 2025 across 88 reported records.
ABBVIE INC. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Qulipta, Ubrelvy, Vumerity, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ubrelvy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Zeposia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REYVOW as an associated drug or biological on 378 records involving 290 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Reyvow by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $591.37 | 26.5% | 36 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $577.45 | 25.9% | 13 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $252.56 | 11.3% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $195.54 | 8.8% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $117.86 | 5.3% | 4 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.49 | 4.6% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $79.07 | 3.5% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $74.19 | 3.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.75 | 2.8% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.98 | 2.2% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.10 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.50 | 1.2% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.48 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.17 | 0.9% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $15.07 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,233.58 | 88 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $591.37 | 36 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $512.35 | 30 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $456.09 | 12 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $228.44 | 9 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $203.05 | 8 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $195.54 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $117.86 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $79.07 | 3 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $71.89 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $61.75 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $49.98 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $45.10 | 2 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $29.04 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 45 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | REYVOW open payments reported associated product |
CMS Open Payments — General Payments 378 supporting records · 290 recipient NPIs · example record 1186470979 |
Reyvow · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 304 | 83 |
| Donepezil Hcl | Donepezil Hcl | 185 | 54 |
| Memantine Hcl | Memantine Hcl | 164 | 48 |
| Baclofen | Baclofen | 154 | 43 |
| Topiramate | Topiramate | 140 | 33 |
| Teriflunomide | Teriflunomide | 130 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 126 | 34 |
| Levetiracetam | Levetiracetam | 126 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 107 | 27 |
| Kesimpta Pen | Ofatumumab | 94 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 21 |
| Primidone | Primidone | 86 | 23 |
| Oxcarbazepine | Oxcarbazepine | 82 | 17 |
| Clonazepam | Clonazepam | 80 | 17 |
| Pregabalin | Pregabalin | 79 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 67 | 23 |
| Lamotrigine | Lamotrigine | 67 | 17 |
| Dalfampridine Er | Dalfampridine | 65 | suppressed |
| Meloxicam | Meloxicam | 65 | 15 |
| Prednisone | Prednisone | 63 | 39 |
| Alprazolam | Alprazolam | 61 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 11 |
| Naratriptan Hcl | Naratriptan Hcl | 58 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 46 | 12 |
| Ubrelvy | Ubrogepant | 45 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 44 | 13 |
| Glatopa | Glatiramer Acetate | 42 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Vumerity | Diroximel Fumarate | 40 | suppressed |
| Amantadine | Amantadine Hcl | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 11 |
| Emgality Pen | Galcanezumab-Gnlm | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Modafinil | Modafinil | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 14 |
| Methylphenidate Hcl | Methylphenidate Hcl | 32 | suppressed |
| Zonisamide | Zonisamide | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Tecfidera | Dimethyl Fumarate | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | 11 |
| Methylprednisolone | Methylprednisolone | 27 | 23 |
| Copaxone | Glatiramer Acetate | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Qulipta | Atogepant | 17 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 15 | suppressed |
| Reyvow | Lasmiditan Succinate | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 13 | suppressed |
| Relpax | Eletriptan Hydrobromide | 13 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,233.58 · 88 records | ABBVIE INC. | AMVUTTRA, AMYVID, AVONEX, BRIUMVI, GOMEKLI, KESIMPTA, KISUNLA, Leqembi, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, QALSODY, QULIPTA, SPINRAZA, Symbravo, TYSABRI, UBRELVY, UPLIZNA, VUMERITY, VYVGART HYTRULO, ZEPOSIA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Qulipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error